



Atty. Dkt. No. 065691-0345  
Appl. Ser. No. 10/727,172

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Abina, Amine

Title: METHOD OF MODULATING  
NEUTRALIZING ANTIBODIES  
FORMATION IN MAMMALS, AND  
USES THEREOF IN GENE THERAPY  
ANIMAL TRANSGENESIS AND IN  
FUNCTIONAL INACTIVATION OF  
ENDOGENOUS PROTEIN(S)

Appl. No.: 10/727,172

Filing Date: 12-03-2003

Examiner: TBD

Art Unit: 1632

<b>CERTIFICATE OF EXPRESS MAILING</b>	
I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.	
EV 431598995 US	April 8, 2004
(Express Mail Label Number)	(Date of Deposit)
Suzanne Langley	
(Printed Name)	
	
(Signature)	

**TRANSMITTAL**

Mail Stop APPLICATION  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Transmitted herewith are the following documents for the above-referenced application:

[ X ] Information Disclosure Statement (3 pages).

[ X ] Form PTO-SB/08 (1 page) and 11 References.

Please direct all correspondence to the undersigned attorney or agent at the address indicated below.

Respectfully submitted,

Date 4/8/04

By M. Scott McBride

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (414) 297-5529  
Facsimile: (414) 297-4900

M. Scott McBride  
Attorney for Applicant  
Registration No. 52,008



Atty. Dkt. No. 065691-0345  
Appl. Ser. No. 10/727,172

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Abina, Amine

Title: METHOD OF MODULATING  
NEUTRALIZING ANTIBODIES  
FORMATION IN MAMMALS,  
AND USES THEREOF IN GENE  
THERAPY, ANIMAL  
TRANSGENESIS AND IN  
FUNCTIONAL INACTIVATION OF  
ENDOGENOUS PROTEIN(S)

Appl. No.: 10/727,172

Filing Date: 12-03-2003

Examiner: TBD

Art Unit: 1632

<b>CERTIFICATE OF EXPRESS MAILING</b>	
I hereby certify that this correspondence is being deposited with the United States Postal Service's "Express Mail Post Office To Addressee" service under 37 C.F.R. § 1.10 on the date indicated below and is addressed to: Commissioner for Patents, PO Box 1450, Alexandria, Virginia 22313-1450.	
EV 431598995 US	April 8, 2004
(Express Mail Label Number)	(Date of Deposit)
Suzanne Langley	
(Printed Name)	
	
(Signature)	

**INFORMATION DISCLOSURE STATEMENT**  
**UNDER 37 CFR §1.56**

Mail Stop APPLICATION  
Commissioner for Patents  
PO Box 1450  
Alexandria, Virginia 22313-1450

Sir:

Submitted herewith on Form PTO/SB/08 is a listing of documents known to Applicant in order to comply with Applicant's duty of disclosure pursuant to 37 CFR §1.56. Copies of those listed documents that were previously cited for U.S. application no. 09/920,902, which is the parent of the instant application, have already been made available to the Examiner. As such, Applicants have included herewith only copies of those documents not previously cited. However, should the Examiner request a copy of any listed document not provided herewith, Applicant will gladly provide the Examiner with a copy.

The submission of any document herewith, which is not a statutory bar, is not intended as an admission that such document constitutes prior art against the claims of the present application or that such document is considered material to patentability as defined in 37 CFR §1.56(b). Applicant does not waive any rights to take any action which would be appropriate to antedate or otherwise remove as a competent reference any document which is determined to be a *prima facie* art reference against the claims of the present application.

#### **TIMING OF THE DISCLOSURE**

The listed documents are being submitted in compliance with 37 CFR §1.97(b)(3), before the first Office Action on the merits.

#### **RELEVANCE OF EACH DOCUMENT**

Any document listed on the attached PTO/SB/08 was cited as being relevant during the prosecution of the corresponding parent application U.S. 09/920,902.

Applicant respectfully requests that any listed document be considered by the Examiner and be made of record in the present application and that an initialed copy of Form PTO/SB/08 be returned in accordance with MPEP §609.

The Commissioner is hereby authorized to charge any additional fees which may be required regarding this application under 37 CFR §§ 1.16-1.17, or credit any overpayment, to Deposit Account No. 06-1447. Should no proper payment be enclosed herewith, as by a check being in the wrong amount, unsigned, post-dated, otherwise improper or informal or even entirely missing, the Commissioner is authorized to charge the unpaid amount to Deposit Account No. 06-1447.

Respectfully submitted,


Date 4/8/04

By M. Scott McBride

FOLEY & LARDNER LLP  
Customer Number: 22428  
Telephone: (414) 297-5529  
Facsimile: (414) 297-4900

M. Scott McBride  
Attorney for Applicant  
Registration No. 52,008

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Date Submitted: April 8, 2004

Use as many sheets as necessary)

Sheet

1

of

3

**Complete if Known**

Application Number	10/727,172
Filing Date	12/03/2003
First Named Inventor	Amine ABINA
Group Art Unit	1632
Examiner Name	Unknown
Attorney Docket Number	065691-0345

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	U.S. Patent Document		Name of Patentee or Applicant of Cited Document	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number	Kind Code <sup>2</sup> (if known)			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Name of Patentee or Applicant of Cited Documents	Date of Publication of Cited Document MM-DD-YYYY	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Office <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				

**OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>6</sup>
		ABINA et al., "Thrombopoietin (TPO) Knockout Phenotype Induced by Cross-Reactive Antibodies Against TPO Following Injection of Mice with Recombinant Adenovirus Encoding Human TPO," The American Association of Immunologists, (1998), pp. 160, 4481-4489.	
		ABONHOUR et al., "Efficient retrovirus-mediated transfer of the multidrug resistance 1 gene into autologous human long-term repopulating hematopoietic stem cells," Nature Medicine, Vol. 6, No. 6, June 2000, pp. 652-658.	
		ALEXANDER et al., "Deficiencies in Progenitor Cells of Multiple Hematopoietic Lineages and Defective Megakaryocytopoiesis in Mice Lacking the Thrombopoietin Receptor c-Mpl," 1996 by the American Society of Hematology, Blood, Vol. 87, No. 6, (March 15, 1996), pp. 2162-2170.	
		ARMENTANO et al., "Characterization of an Adenovirus Gene Transfer Vector Containing an E4 Deletion," Human Gene Therapy 6:1343-1353 (October 1995).	
		ARMENTANO et al., "Effect of the E4 Region on the Persistence of Transgene Expression from Adenovirus Vectors," Journal of Virology, (March 1997), pp. 2408-2416, Vol. 71, No. 3, American Society for Microbiology	
		BERKNER et al., "Expression of Heterologous Sequences in Adenoviral Vectors; Current Topics in Microbiology and Immunology," Vol. 158, Springer-Verlag Berlin-Heidelberg (1992), pp. 39-66.	
		CARVER-MOORE et al., "Low Levels of Erythroid and Myeloid Progenitors in Thrombopoietin and C mpl - Deficient Mice," The American Society of Hematology, Blood, Vol. 88, No. 3 (August 1, 1996), pp. 803-808.	
		ERTL et al., "Genetic immunization," 1996, VIRAL IMMUNOLOGY, Vol. 9, pp. 1-9.	
		FANG et al., "Gene Therapy for Hemophilia B: Host Immunosuppression Prolongs the Therapeutic Effect of Adenovirus-Mediated Factor IX Expression, Human Gene Therapy," (August 1995), pp. 6:1039-1044	
		FISHER et al., "Recombinant Adenovirus Deleted of All Viral Genes for Gene Therapy of Cystic Fibrosis," Virology 217, Article No. 0088 (1996), pp. 11-22.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

002.1177548.1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	
				10/727,172	
				Filing Date	
				12/03/2003	
				First Named Inventor	
Date Submitted: April 8, 2004				Amine ABINA	
(use as many sheets as necessary)				Group Art Unit	
				1632	
				Examiner Name	
				Unknown	
Sheet	2	of	3	Attorney Docket Number	
				065691-0345	

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6	
		GALLO-PENN et al., "Systemic delivery of an adenoviral vector encoding canine factor VIII results in short-term phenotypic correction, inhibitor development, and biphasic liver toxicity in hemophilia A dogs," Blood, January 1, 2001, Vol. 97, No. 1, pp. 107-113.		
		GE et al., "Factors influencing the development of an anti-factor IX (FIX) immune response following administration of adeno-associated virus-FIX," Blood, June 15, 2001, Vol. 97, No. 12, pp. 3733-3737.		
		GORZIGLIA et al., "Elimination of both E1 and E2a from Adenovirus Vectors Further Improves Prospects for In Vivo Human Gene Therapy," Journal of Virology, Vol. 70, No. 6 (June 1996), pp. 4173-4178.		
		GOUGH et al., "Structure and Expression of the mRNA for Murine Granulocyte-Macrophage Colony Stimulating Factor," The EMBO Journal, Vol. 4 No. 3 (1985), pp. 645-653.		
		GRAHAM et al., "Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5," J. Gen. Virol., Vol. 36, (1977), pp. 59-72.		
		GUO et al., "Evaluation of Promoter Strength for Hepatic Gene Expression In Vivo Following Adenovirus-mediated Gene Transfer," Gene Therapy, Vol. 3, (1996), pp. 802-810.		
		HO et al., "Site-directed Mutagenesis by Overlap Extension Using the Polymerase Chain Reaction," Gene, 77, (1989), pp. 51-59.		
		HOSTOMSKY et al., "High-level Expression of Self-Processed HIV-1 Protease in Escherichia Coli Using a Synthetic Gene," Biochemical and Biophysical Research Communications, Vol. 161, No. 3, (June 30, 1989), pp. 1056-1063.		
		IMLER et al., "Novel Complementation Cell Lines Derived from Human Lung Carcinoma A549 Cells Support the Growth of E1-deleted Adenovirus Vectors," Gene Therapy, Vol. 3, (1996), pp. 75-84.		
		JOLLY, "Viral Vector Systems for Gene Therapy, Cancer Gene Therapy," Vol. 1, No. 1, (1994) pp. 51-64.		
		KAPLAN et al., "Characterization of Factors Involved in Modulating Persistence of Transgene Expression from Recombinant Adenovirus in the Mouse Lung," Human Gene Therapy, Vol. 8, (January 1, 1997), pp. 45-56.		
		KAY et al., "Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector," Nature America, Inc., Vol. 24, March 2000, pp. 257-261.		
		KAY et al., "Long-term Hepatic Adenovirus-mediated Gene Expression in Mice Following CTLA4Ig Administration," Nature Genetics, Vol. 11, (October 1995), pp. 191-197.		
		KOCHANNEK et al., "A New Adenoviral Vector: Replacement of All Viral Coding Sequences With 28 kb of DNA Independently Expressing Both Full-length Dystrophin and $\beta$ -galactosidase," Proc. Natl. Acad. Sci. USA, Vol. 93, (June 1996), pp. 5731-5736.		
		LIEBER et al., "Recombinant Adenoviruses with Large Deletions Generated by Cre-Mediated Excision Exhibit Different Biological Properties Compared with First-Generation Vectors In Vitro and In Vivo," Journal of Virology, Vol. 70, No. 12, (Dec. 1996), pp. 8944-8960.		
		MAIONE et al., "An Improved Helper-Dependent Adenoviral Vector Allows Persistent Gene Expression After Intramuscular Delivery and Overcomes Preexisting Immunity to Adenovirus," PNAS, Vol. 98, No. 11, (May 22, 2001), pp. 5986-5991.		
		MARSHALL et al., "Gene therapy's growing pains," 1995, SCIENCE, Vol. 269, pp. 1050-1055.		
		MYERS et al., "A General Method for Saturation Mutagenesis of Cloned DNA Fragments," Science, Vol. 229, (July 19, 1985), pp. 242-247.		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO				<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>				Application Number	
				10/727,172	
				Filing Date	
				12/03/2003	
				First Named Inventor	
Date Submitted: April 8, 2004				Amine ABINA	
(use as many sheets as necessary)				Group Art Unit	
				1632	
Sheet 3 of 3				Examiner Name	
				Unknown	
				Attorney Docket Number	
				065691-0345	

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 6	
		NEEDLEMAN et al., "A General Method Applicable to the Search for Similarities in the Amino Acid Sequence of Two Proteins," J. Mol. Biol., Vol. 48, (1970), pp. 443-453.		
		ORKIN et al., "Report and recommendations of the panel to assess the NIH investment in research on gene therapy," 1995, NIH.		
		PANOUTSAKOPOULOU et al., "Analysis of the Relationship between Viral Infection and Autoimmune Disease," Immunity, Vol. 15, pp. 137-147, July 2001, Cell Press.		
		PEARSON et al., "Improved Tools for Biological Sequence Comparison," Proc. Natl. Acad. Sci. USA, Vol. 85, (April 1988) pp. 2444-2448.		
		ROSS et al., "Gene therapy in the United States: A five-year status report," 1996, HUMAN GENE THERAPY, Vol. 7, pp. 1781-1790.		
		SMITH et al., "Comparison of Biosequences, Advances in Applied Mathematics," Vol. 2, (1981), pp. 482-489.		
		STRATFORD-PERRICAUDET et al., "Evaluation of the Transfer and Expression in Mice of an Enzyme-Encoding Gene Using a Human Adenovirus Vector, Human Gene Therapy," Vol. 1, (1990), pp. 241-256.		
		TIZARD, "Immunology An Introduction," Second Edition, Saunders College Publishing, (1988), pp. 264-270.		
		TRIPATHY et al., "Immune Responses to Transgene-encoded Proteins Limit the Stability of Gene Expression After Injection of Replication-Defective Adenovirus Vectors," Nature Medicine, Vol. 2, No. 5, (May 1996), pp. 545-550.		
		VERMA et al., "Gene therapy : promises, problems and prospects," 1997, NATURE, Vol. 389, pp. 239-242.		
		WENDLING et al., "c-Mpl Ligand is a Humoral Regulator of Megakaryocytopoiesis," Nature, Vol. 369, (June 16, 1994), pp. 571-574.		
		WUCHERPFENNIG et al., "Molecular Mimicry in T Cell-Mediated Autoimmunity: Viral Peptides Activate Human T Cell Clones Specific for Myelin Basic Protein," Cell Press, Vol. 80, 695-705, March 10, 1995		
		YANG et al., "Cellular Immunity to Viral Antigens Limits E1-deleted Adenoviruses for Gene Therapy," Proc. Natl. Acad. Sci. USA, Vol. 91, (May 1994), pp. 4407-4411.		
		YANG et al., "Immune Responses to Viral Antigens Versus Transgene Product in the Elimination of Recombinant Adenovirus-Infected Hepatocytes In Vivo," Gene Therapy, Vol. 3, (1996), pp. 137-144.		
		YANG et al., "Inactivation of E2a in Recombinant Adenoviruses Improves the Prospect for Gene Therapy in Cystic Fibrosis," Nature Genetics, Vol. 7, (July 1994), pp. 362-369.		
		YANG et al., "MHC Class I-Restricted Cytotoxic T Lymphocytes to Viral Antigens Destroy Hepatocytes in Mice Infected with E1-Deleted Recombinant Adenoviruses," Immunity, Vol. 1, (August, 1994), pp. 433-442.		
		YANG et al., "Role of Viral Antigens in Destructive Cellular Immune Responses to Adenovirus Vector-Transduced Cells in Mouse Lungs," Journal of Virology, Vol. 70, No. 10, (October 1996), pp. 7209-7212.		
		ZI-SHAN et al., "Molecular Mimicry by Herpes Simplex Virus-Type 1: Autoimmune Disease After Viral Infection," Science, Vol. 279, February 27, 1998, pp. 1344-1347.		
		ZSENGELLER et al., "Persistence of Replication-Deficient Adenovirus-Mediated Gene Transfer in Lungs of Immune-Deficient (nu/nu) Mice," Human Gene Therapy, Vol. 6, (April 1995) pp. 457-467.		

Examiner Signature	Date Considered
--------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup>See attached Kinds of U.S. Patent Documents. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.